Lanisidenib|CAS 2135537-20-9|DC Chemicals

Cas No.:	2135537-20-9
Chemical Name:	Lanisidenib
SMILES:	FC(F)(C1)CC1NC([C@H](C2=C(C=CC=C2)Cl)N(C3=CC(F)=CC=C3)C([C@H]4N(C5=CC(C#N)=CC=N5)S(=O)(CC4)=O)=O)=O
Formula:	C₂₈H₂₃ClF₃N₅O₄S
M.Wt:	618.03
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC44726	Enasidenib Mesylate	Enasidenib (Idhifa, AG-221) mesylate is an orally available, selective and potent inhibitor of mutant isocitrate dehydrogenase 2 (IDH2).
DC28576	DS-1001b	DS-1001b is a mutant IDH-1 (Isocitrate Dehydrogenase-1) inhibitor extracted from patent WO2016052697A1, Example 168, and has antitumor activity.
DC76857	Lanisidenib	Lanisidenib is the inhibitor for isocitrate dehydrogenase that exhibits antineoplastic activity.
DC76856	Crelosidenib (gentisate)	Crelosidenib (gentisate) is a potent, selective and orally active mutant isocitrate dehydrogenase (IDH) inhibitor with IC50 of 6.27 nM, 3.71 nM, 36.9 nM and 11.5 nM for IDH1 R132H, IDH1 R132C, IDH2 R140Q and IDH2 R172K mutant enzymes, respectively. Crelosidenib (gentisate) is less active at inhibiting the IDH wild-type enzymes.
DC72374	(S,S)-GSK321	(S,S)-GSK321 is a (S,S)-enantiomer of GSK321.
DC70642	NCATS-SM5637	NCATS-SM5637 (NSC 791985) is a potent, selective mutant IDH1 inhibitor with IC50 of 81/72 nM for IDH1 mutant R132H/R132C, respctively.NCATS-SM5637 showed higher tumoral concentrations that corresponded to lower 2-HG concentrations in engineered mIDH1-U87-xenograft mouse model, compared with the approved drug AG-120 (ivosidenib).
DC49742	AGI-12026	AGI-12026 is brain-penetrant dual inhibitor of mutant IDH1 and 2. AGI-12026 shows partial inhibition of the IDH1-R132H homodimer as allosteric modulators. AGI-12026 has the potential for research of glioma.
DC48219	Safusidenib	Safusidenib is a novel IDH1 inhibitor for the treatment of IDH1-mutated tumors.